Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Nucala Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Nucala (mepolizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Part B prior authorization and coverage criteria for Nucala (mepolizumab) for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. It applies to providers requesting initial coverage or reauthorization for eligible members.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyNucala (mepolizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with disease-specific criteria, supporting medical records, and documented clinical benefit for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3FDA-approved covered use categories
    ≥150 cells/mcLRecent asthma eosinophil threshold
    ≥1,000 cells/mcLHES eosinophil threshold
    1 year / 2 yearsInitial / reauthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredSpecialist prescriber requirement

    Covered Uses and Reauthorization

    Initial Severe Eosinophilic Asthma

    Covered for initial severe eosinophilic asthma when ALL of the following criteria are met:

    ALL of the following

    • Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • ONE of the following eosinophil criteria

      • The eosinophil level is elevated.>= 150 cells/mcL within 6 weeks prior to the immediate start of treatment with Nucala
      • The eosinophil level is elevated.>= 300 cells/mcL in the previous 12 months
    • The member must try and fail one ICS/LABA inhaler drug in the past six months. Failure is defined as intolerance or inability to improve the condition despite required therapy for at least four weeks.

    Reauthorization — Severe Eosinophilic Asthma

    Covered for reauthorization of severe eosinophilic asthma when ALL of the following criteria are met:

    ALL of the following

    • Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • The member must have clinical benefit from Nucala, such as decreased exacerbations, improvement in symptoms, or decreased oral steroid use.

    Initial Hypereosinophilic Syndrome (HES)

    Covered for initial hypereosinophilic syndrome (HES) when ALL of the following criteria are met:

    ALL of the following

    • Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • The blood eosinophil count is at least 1,000 cells/mcL.>= 1,000 cells/mcL
    • The member has had HES for at least six months.>= 6 months
    • The member has had at least two HES flares in the past year. A flare is defined as symptoms requiring a steroid or an increase in the current steroid dose.>= 2 flares in the past year

    Reauthorization — Hypereosinophilic Syndrome (HES)

    Covered for reauthorization of hypereosinophilic syndrome (HES) when ALL of the following criteria are met:

    ALL of the following

    • Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • The member must have clinical benefit from Nucala, such as decreased exacerbations, improvement in symptoms, or decreased steroid use.

    Nucala must not be used in combination with other biologic drugs.

    Clinical Thresholds and Treatment Requirements

    Recent eosinophil count for severe eosinophilic asthma
    Minimum eosinophil count≥150 cells/mcL
    TimingWithin six weeks before the immediate start of treatment with Nucala
    Applicable useInitial coverage of severe eosinophilic asthma
    Historical eosinophil count for severe eosinophilic asthma
    Minimum eosinophil count≥300 cells/mcL
    Lookback periodWithin the previous 12 months
    Applicable useInitial coverage of severe eosinophilic asthma when the recent six-week threshold is not used

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Disease-Specific Criteria

    Prior authorization is required for Nucala (mepolizumab) initial coverage and reauthorization. Coverage is limited to FDA-approved uses—severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES)—when the applicable disease-specific criteria are met.

    • Initial authorization period: one year; reauthorization period: two years.
    • Dose must follow FDA-approved labeling or accepted standards of medical practice.
    • Nucala must not be used in combination with another biologic drug.
    Prior Authorization

    Specialist Prescriber or Consultation Required

    The prescriber must be a specialist or must have consulted with a specialist for the condition being treated.

    • Document the specialist prescriber or consulting specialist and the condition addressed.

    Medication and Covered Conditions

    Nucala (mepolizumab) is an interleukin-5 (IL-5) antagonist indicated for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). Coverage requirements vary by condition and may include eosinophil levels, prior treatment history, disease activity, and documented clinical benefit.

    Policy Terms

    ICS/LABA inhaler
    CombinationInhaled corticosteroid plus long-acting beta agonist
    Dosage formCombination inhaler
    Use in the policyOne ICS/LABA inhaler is required as prior therapy for initial severe eosinophilic asthma coverage
    Asthma treatment failure
    Treatment failureIntolerance or inability to improve the condition
    Required therapy durationThe member must receive the required therapy for at least four weeks
    Policy application

    Initial Coverage Criteria

    Initial Severe Eosinophilic Asthma

    Nucala is covered for severe eosinophilic asthma when all applicable initial criteria are met.

    Initial severe eosinophilic asthma

    • Supporting records: Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • Eosinophil threshold

      • Recent eosinophil count: The member has an eosinophil level of at least 150 cells/mcL within six weeks before the immediate start of treatment with Nucala.≥150 cells/mcL within six weeks
      • Historical eosinophil count:

    Reauthorization Criteria

    Reauthorization Clinical Benefit

    Reauthorization requires supporting medical records and documented clinical benefit.

    Reauthorization clinical benefit

    • Supporting records: Medical records supporting the reauthorization request, including documentation of prior therapies and responses to treatment, must be provided.
    • Clinical benefit

      • Reduced exacerbations: Exacerbations have decreased.
      • Improved symptoms: Symptoms have improved.

    Required Prior Treatment

    StepIndicationRequired prior therapyTimeframeFailure definition
    1Severe eosinophilic asthmaTry and fail one ICS/LABA inhalerTrial within the past six months; required therapy for at least four weeksIntolerance or inability to improve the condition
    StepIndicationRequired prior therapyTimeframeFailure definition
    1Hypereosinophilic syndrome (HES)Try and fail a generic steroid-sparing drug, such as methotrexate or hydroxyureaBefore initial Nucala coverageInability to improve symptoms
    Policy Summary
    PayerGold Coast Health Plan
    PolicyNucala (mepolizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with disease-specific criteria, supporting medical records, and documented clinical benefit for reauthorization.
    SourceLink
    On This Page
    Covered Uses and ReauthorizationClinical Thresholds and Treatment RequirementsAuthorization and Documentation RequirementsMedication and Covered ConditionsPolicy TermsInitial Coverage CriteriaReauthorization CriteriaRequired Prior Treatment
  1. The provider attests that there is no identifiable non-hematologic secondary cause of HES.
  2. The member must try and fail a generic steroid-sparing drug, such as methotrexate or hydroxyurea. Failure is defined as an inability to improve symptoms.
  3. Blood eosinophil count for HES
    Minimum blood eosinophil count≥1,000 cells/mcL
    Applicable conditionHypereosinophilic syndrome (HES)
    Authorization phaseInitial HES coverage
    HES duration
    Minimum durationAt least six months
    ConditionHypereosinophilic syndrome (HES)
    Authorization phaseInitial HES coverage
    HES flares
    Minimum number of flaresAt least two
    Lookback periodDuring the past year
    Flare definitionSymptoms requiring a steroid or an increase in the current steroid regimen
    ICS/LABA treatment trial
    Minimum treatment durationAt least four weeks of required therapy
    Trial recencyThe trial must occur within the past six months
    Required therapyOne ICS/LABA inhaler before initial Nucala coverage for severe eosinophilic asthma
    Step Therapy

    ICS/LABA Trial Required

    For initial coverage of severe eosinophilic asthma, document a trial of and failure of at least one ICS/LABA inhaler within the past six months.

    • Failure means intolerance or inability to improve the condition despite at least four weeks of required therapy.
    Step Therapy

    Generic Steroid-Sparing Therapy Required

    For initial HES coverage, document a trial of and failure of a generic steroid-sparing medication, such as methotrexate or hydroxyurea.

    • Failure is defined as an inability to improve symptoms.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Initial-Criteria Denial Risk

    Initial coverage may be denied when required disease-specific criteria are missing or unsatisfied, including required records, laboratory thresholds, prior-treatment failures, disease duration or flare history, or the HES secondary-cause attestation.

    • Asthma: required eosinophil threshold and failed ICS/LABA trial must be documented.
    • HES: document eosinophils >= 1,000 cells/mcL, HES for at least six months, at least two flares in the past year, no identifiable non-hematologic secondary cause, and failed generic steroid-sparing therapy.
    Denial Risk

    No Documented Clinical Benefit

    Reauthorization may be denied when submitted records do not demonstrate clinical benefit from Nucala or do not include the required treatment and response documentation.

    • Document changes such as fewer exacerbations, improved symptoms, or reduced oral steroid or other steroid use, as applicable to the condition.
    Defines failure of the required ICS/LABA inhaler trial for initial severe eosinophilic asthma coverage
    HES flare
    HES flareSymptoms requiring a steroid or an increase in the current steroid regimen
    ConditionHypereosinophilic syndrome (HES)
    Counting periodFlares are counted during the past year
    HES treatment failure
    Treatment failureInability to improve symptoms with the medication
    Applicable therapyA generic steroid-sparing drug, such as methotrexate or hydroxyurea
    Policy applicationDefines failure required for initial HES coverage
    Clinical benefit
    Reduced exacerbationsA decrease in exacerbations
    Improved symptomsImprovement in symptoms
    Reduced steroid useA decrease in oral steroid or steroid use
    The member has an eosinophil level of at least 300 cells/mcL in the previous 12 months.
    ≥300 cells/mcL within the previous 12 months
  4. Prior ICS/LABA therapy: The member has tried and failed one ICS/LABA inhaler in the past six months.At least one trial within the past six months

    Failure means intolerance or inability to improve the condition on required therapy for at least four weeks.

  5. Initial Hypereosinophilic Syndrome

    Nucala is covered for initial hypereosinophilic syndrome therapy when all criteria are met.

    Initial hypereosinophilic syndrome

    • Supporting records: Medical records supporting the request, including documentation of prior therapies and responses to treatment, must be provided.
    • Blood eosinophil count: The member has a blood eosinophil count of at least 1,000 cells/mcL.≥1,000 cells/mcL
    • Disease duration: The member has had hypereosinophilic syndrome for at least six months.At least six months
    • Disease flares: The member has had at least two hypereosinophilic syndrome flares in the past year.At least two flares in the past year

      A flare is defined as symptoms requiring a steroid or an increase in the current steroid regimen.

    • Secondary cause assessment: The provider attests that there is no identifiable non-hematologic secondary cause of hypereosinophilic syndrome.
    • Steroid-sparing therapy: The member has tried and failed a generic steroid-sparing drug, such as methotrexate or hydroxyurea.

      Failure means an inability to improve symptoms.

    Reduced steroid use: Oral steroid or steroid use has decreased.